Caligan Partners' Dave Johnson on MorphoSys' $MOR change from royalty play to traditional biotech
Episode Date: June 16, 2023Dave Johnson, Managing Partner at Caligan Partners, makes his second appearance to discuss his thesis on MorphoSys AG (FSE: MOR; NASDAQ: MOR), includi...